EUVIMEDEUVIMED entdecken
Crossref

Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab

Giulia Maddalena iD, Ymke van der Pol iD, Oscar E Villarreal iD, Oluwadara Coker iD, Hey Min Lee iD, Zach Rivers iD, Wendy Covert iD, Stacy Diao iD, Sara Lonardi iD, Jane E Rogers iD, Arvind Dasari iD, Justin Guinney iD und 2 weitere

JNCI: Journal of the National Cancer Institute · 2026

DOI: 10.1093/jnci/djaf385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Giulia Maddalena und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: CPRIT Research Training.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical benefit from later lines of therapy in metastatic colorectal cancer (mCRC) is limited. Patient selection for treatment is crucial for optimal risk-benefit evaluation. Codon-specific KRAS mutations have been implicated as predictive biomarkers for efficacy of trifluridine/tipiracil (TAS-102). However, their predictive impact for TAS-102 plus Bevacizumab (TAS-Bev), the new standard of care in mCRC, is unknown.

Methods

This large patient-based, real-world, retrospective cohort study of mCRC patients who received TAS-102 alone or in combination with bevacizumab between January 1, 2020, and March 1, 2023. A sensitivity analysis was performed in 2 independent cohorts from MD Anderson Cancer Center, Houston, TX, and Tempus AI, Inc., Chicago, IL, prior to polling the data together.

Results

A total of 946 mCRC patients were evaluated; KRAS was mutated in 57.8% cases, 39.4% involving G12 codon, and 9.8% G13. We found no association of KRAS-G12 mutations with overall survival (hazard ratio [HR] = 1.1, 95% confidence interval [CI] = 0.90 to 1.25; P = .441) on TAS-102 contradicting the reported predictive impact of these biomarkers. Moreover, we reported inferior overall survival for KRAS-G13 mutant patients (HR = 1.3, 95% CI = 1.02 to 1.69; P = .045). On TAS-Bev, no association was found between KRAS-G12 (HR = 0.8, 95% CI = 0.59 to 1.11; P = .188) or KRAS-G13 (HR = 1.66, 95% CI = 0.99 to 2.79; P = .072) mutations and overall survival.

Conclusions

No significant associations between KRAS-G12 and overall survival were found for TAS-102 or TAS-Bev. Further research is needed to assess the impact of these mutations on combined TAS-Bev therapy prior to any clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMutationHumansTrifluridineMaleFemalePyrrolidinesDrug CombinationsBevacizumabMiddle AgedAgedThymineRetrospective StudiesCodonUracilAged, 80 and overAdultBiomarkers, Tumor

Substanzen

TrifluridineProto-Oncogene Proteins p21(ras)PyrrolidinesDrug CombinationsKRAS protein, humantrifluridine tipiracil drug combinationBevacizumabThymineCodonUracil

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padova, Italy.
  • Tempus AI, Inc, Chicago, IL, United States.
  • Pharmacy Clinical Programs U.T. M.D. Anderson Cancer Center, Houston, TX, United States.

ORCID-Profile: Giulia Maddalena, Ymke van der Pol, Oscar E Villarreal, Oluwadara Coker, Hey Min Lee, Zach Rivers, Wendy Covert, Stacy Diao, Sara Lonardi, Jane E Rogers, Arvind Dasari, Justin Guinney, Scott Kopetz, Kanwal Raghav

Förderung

  • CPRIT Research Training

Zitieren

APA

Maddalena, G., van der Pol, Y., Villarreal, O. E., Coker, O., Min Lee, H., Rivers, Z., Covert, W., Diao, S., Lonardi, S., Rogers, J. E., Dasari, A., Guinney, J., Kopetz, S., & Raghav, K. (2026). Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf385

Vancouver

Maddalena G, van der Pol Y, Villarreal OE, Coker O, Min Lee H, Rivers Z, et al. Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf385

BibTeX
@article{Maddalena2026,
  author = {Maddalena, Giulia and van der Pol, Ymke and Villarreal, Oscar E and Coker, Oluwadara and Min Lee, Hey and Rivers, Zach and Covert, Wendy and Diao, Stacy and Lonardi, Sara and Rogers, Jane E and Dasari, Arvind and Guinney, Justin and Kopetz, Scott and Raghav, Kanwal},
  title = {Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  doi = {10.1093/jnci/djaf385}
}
Kostenlos starten →